137 related articles for article (PubMed ID: 12507558)
1. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies.
Dantuma NP; Masucci MG
Semin Cancer Biol; 2003 Feb; 13(1):69-76. PubMed ID: 12507558
[TBL] [Abstract][Full Text] [Related]
2. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
3. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
Kelly GL; Milner AE; Baldwin GS; Bell AI; Rickinson AB
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14935-40. PubMed ID: 17001014
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system.
Masucci MG
Oncogene; 2004 Mar; 23(11):2107-15. PubMed ID: 15021898
[TBL] [Abstract][Full Text] [Related]
5. EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma.
Ruf IK; Rhyne PW; Yang H; Borza CM; Hutt-Fletcher LM; Cleveland JL; Sample JT
Curr Top Microbiol Immunol; 2001; 258():153-60. PubMed ID: 11443860
[No Abstract] [Full Text] [Related]
6. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.
Levitskaya J; Sharipo A; Leonchiks A; Ciechanover A; Masucci MG
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12616-21. PubMed ID: 9356498
[TBL] [Abstract][Full Text] [Related]
7. Burkitt lymphoma--a stalking horse for cancer research?
Klein G
Semin Cancer Biol; 2009 Dec; 19(6):347-50. PubMed ID: 19607918
[TBL] [Abstract][Full Text] [Related]
8. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells.
Gavioli R; Frisan T; Vertuani S; Bornkamm GW; Masucci MG
Nat Cell Biol; 2001 Mar; 3(3):283-8. PubMed ID: 11231578
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
Longnecker R
Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines.
Touitou R; Arbach H; Cochet C; Feuillard J; Martin A; Raphaël M; Joab I
J Gen Virol; 2003 Apr; 84(Pt 4):949-957. PubMed ID: 12655096
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease.
Hammerschmidt W; Sugden B
Trends Mol Med; 2004 Jul; 10(7):331-6. PubMed ID: 15242681
[TBL] [Abstract][Full Text] [Related]
12. Avoiding proteasomal processing: the case of EBNA1.
Dantuma NP; Sharipo A; Masucci MG
Curr Top Microbiol Immunol; 2002; 269():23-36. PubMed ID: 12224511
[TBL] [Abstract][Full Text] [Related]
13. Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells.
Leao M; Anderton E; Wade M; Meekings K; Allday MJ
J Virol; 2007 Jan; 81(1):248-60. PubMed ID: 17035311
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus: induction and control of cell transformation.
Dolcetti R; Masucci MG
J Cell Physiol; 2003 Aug; 196(2):207-18. PubMed ID: 12811813
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
Kelly G; Bell A; Rickinson A
Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of c-myc in lymphoblastoid cells does not support an Epstein-Barr virus latency III-to-I switch.
Pajic A; Polack A; Staege MS; Spitkovsky D; Baier B; Bornkamm GW; Laux G
J Gen Virol; 2001 Dec; 82(Pt 12):3051-3055. PubMed ID: 11714983
[TBL] [Abstract][Full Text] [Related]
17. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link.
Kelly GL; Long HM; Stylianou J; Thomas WA; Leese A; Bell AI; Bornkamm GW; Mautner J; Rickinson AB; Rowe M
PLoS Pathog; 2009 Mar; 5(3):e1000341. PubMed ID: 19283066
[TBL] [Abstract][Full Text] [Related]
18. Degradation of the epstein-barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue.
Aviel S; Winberg G; Massucci M; Ciechanover A
J Biol Chem; 2000 Aug; 275(31):23491-9. PubMed ID: 10807912
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Zou P; Kawada J; Pesnicak L; Cohen JI
J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.
Kennedy G; Komano J; Sugden B
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14269-74. PubMed ID: 14603034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
